High-throughput arrays identify distinct genetic profiles associated with lymph node involvement in rectal cancer

Diseases of the Colon and Rectum

Volumn 55, Issue 6, 2012, Pages 628-639

  Kalady, Matthew F ^a   Coffey, J Calvin ^b   DeJulius, Kathryn ^a   Jarrar, Awad ^a   Church, James M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Gene signature; Lymph node; Metastasis; Microarray; Rectal cancer; Stage III

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A SYNTHASE GENE; ADULT; AGED; ARTICLE; CANCER STAGING; CARBONIC ANHYDRASE GENE; CHEMORADIOTHERAPY; CYSTATIN GENE; DNA MICROARRAY; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE MAPPING; GENETIC ANALYSIS; GENETIC DIFFERENCE; HUMAN; HUMAN TISSUE; INTERLEUKIN 8 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; RECTUM CANCER; RECTUM CARCINOMA; UBIQUITIN GENE;

ADENOCARCINOMA; AGED; BAYES THEOREM; CARBONIC ANHYDRASES; CHI-SQUARE DISTRIBUTION; CYSTATINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; INTERLEUKIN-8; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECTAL NEOPLASMS; SOFTWARE; STATISTICS, NONPARAMETRIC; UBIQUITIN;

EID: 84863628867     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e3182507511     Document Type: Article

References (33)

1. Skandarajah AR, Tjandra JJ. Preoperative loco-regional imaging in rectal cancer. ANZ J Surg. 2006;76:497-504. (Pubitemid 43846477)
2. Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for predicting the risk factors-the circumferential resection margin and nodal disease-of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR. 2005;26:259-268. (Pubitemid 41111583)
3. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol. 2006;13:1386-1392. (Pubitemid 44749649)
4. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J Mol Diagn. 2007;9:563-571. (Pubitemid 350158413)
5. Zauber NP, Wang C, Lee PS, Redondo TC, Bishop DT, Goel A. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol. 2004;57:938-942. (Pubitemid 39208244)
6. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
7. Kalady MF, DeJulius K, Church JM, Lavery IC, Fazio VW, Ishwaran H. Gene signature is associated with early stage rectal cancer recurrence. J Am Coll Surg. 2010;211:187-195.
8. Hao J-M, Chen J-Z, Sui H-M, et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010;220:475-489.
9. Melis M, Hernandez J, Siegel EM, et al. Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum. 2010;53:936-943.
10. Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer. 2009;115:283-292.
11. Croner RS, Fortsch T, Bruckl WM, et al. Molecular signature for lymphatic metastasis in colorectal carcinomas. Ann Surg. 2008;247:803-810. (Pubitemid 351591515)
12. Watanabe T, Kobunai T, Tanaka T, Ishihara S, Matsuda K, Nagawa H. Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum. 2009;52:1941-1948.
13. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum. 2009;52:1039-1045.
14. Sanchez JA, Krumroy L, Plummer S, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg. 2009;96:1196-1204.
15. Smyth GK. Linear models and empirical Bayes methods forassessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis ofmicroarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-5121. (Pubitemid 32397092)
17. Elo LL, Filen S, Lahesmaa R, Aittokallio T. Reproducibility-optimized test statistic for ranking genes in microarray studies. IEEE/ACM Trans Comput Biol Bioinform. 2008;5:423-431.
18. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis. 2010;11:50-54.
19. Li DW, Tang HM, Fan JW, et al. Expression level of Bmi-1oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2010;136:997-1006.
20. Bates RC, DeLeo MJ III, Mercurio AM. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 2004;299:315-324. (Pubitemid 39179799)
21. Kivela AJ, Kivela J, Saarnio J, Parkkila S. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol. 2005;11:155-163. (Pubitemid 40125196)
22. Hedley D, Pintilie M, Woo J, et al. Carbonic anhydrase IXexpression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res. 2003;9:5666-5674. (Pubitemid 37499489)
23. Rajaganeshan R, Prasad R, Guillou PJ, Scott N, Poston G, Jayne DG. Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol. 2009;35:1286-1294.
24. Liu YL, Yang YM, Xu H, Dong XS. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25:1800-1805.
25. Yan DW, Li DW, Yang YX, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer. 2010;103:961-969.
26. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, et al. Gene expression in colorectal cancer. Cancer Res. 2002;62:4352-4363. (Pubitemid 34827293)
27. Camarero N, Mascaro C, Mayordomo C, Vilardell F, Haro D, Marrero PF. Ketogenic HMGCS2 is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer. Mol Cancer Res. 2006;4:645-653. (Pubitemid 44497217)
28. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(suppl 1):i104-i108.
29. Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 2009;69:338-348.
30. Komori T, Takemasa I, Yamasaki M, et al. Gene expression of colorectal cancer: preoperative genetic diagnosis using endoscopic biopsies. Int J Oncol. 2008;32:367-375. (Pubitemid 351188303)
31. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA.Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem. 2010;52:19-39.
32. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54:295-308. (Pubitemid 40073988)
33. Quasar Collaborative G, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-2029.